Biotech · Private company · Tarrytown, NY, US
Sapience Therapeutics
Track this companyFree. Adds Sapience Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials22 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- RadiationPhase 2 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
- ST101Phase 2 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
- TemozolomidePhase 2 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
- FOLFIRI regimen & bevacizumabPhase 1 · Colon CancerClinicalTrials.gov · fetched Nov 12, 2026
- FruquintinibPhase 1 · Colon CancerClinicalTrials.gov · fetched Nov 12, 2026
- Lonsurf & bevacizumabPhase 1 · Colon CancerClinicalTrials.gov · fetched Nov 12, 2026
- ST316Phase 1 · Colon CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Jun 5, 2023ClinicalTrials.gov NCT05848739 · fetched Nov 12, 2026
- A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jul 1, 2020ClinicalTrials.gov NCT04478279 · fetched Nov 12, 2026
NIH awards1
- Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancerFiscal year 2024 · $632.1KNIH RePORTER 5R44CA265503-03 · fetched Nov 12, 2026